CJC-1295 No DAC / Modified GRF(1-29)

ID: modified_grf_129

Aliases: CJC-1295 No DAC, Mod GRF 1-29, modified GRF(1-29), tetrasubstituted GRF(1-29), CJC-1295 (NO DAC)

Type: compound

Route/form: subcutaneous injection in published endocrine/research contexts; no-DAC naming needs molecule-specific evidence

Status: research

Evidence level: early human

Best data tier: human physiology

Support scope: human, non-human/mechanistic

Source types: human_physiology, preclinical

Linked sources: 3

Broad outcomes: Brain / mood / sleep, Fat loss / metabolic health, Hormones / fertility / sexual health, Muscle growth / performance / recovery, PEDs / AAS / thermogenics

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• GHRH receptor agonism
• short-pulse GH release
• GH/IGF-1 axis stimulation

Optimization domains

• growth hormone
• body composition
• sleep
• recovery

Research basis

• Modified GRF(1-29)/CJC-1295 no-DAC belongs in the database because it represents short-acting GHRH analog exposure rather than the multi-day DAC profile.
• Human GRF(1-29) literature supports acute pituitary GH release and diagnostic physiology; pairing logic with GHRP-class agonists is mechanistically coherent.
• Best supported claim is GH-axis stimulation, not a direct anabolic or anti-aging outcome.

Limits, risks, and missing evidence

• Human outcome data for recovery, hypertrophy, sleep, or fat loss are thin compared with the endocrine biomarker data.
• Response depends on pituitary reserve, sleep/nutrition state, somatostatin tone, and baseline GH/IGF physiology.
• GH-axis adverse effects remain relevant even when the peptide is short acting.

Risk flags

• investigational
• endocrine axis
• gh igf1 axis
• outcome extrapolation

Linked papers, labels, and reviews

1. Does growth hormone releasing factor desensitize the somatotrophbeta Responses during and after 10-hour infusion of GRF 1-29 amide in man
   human_physiology / pubmed_grf129_infusion_men_1986
   Human GRF(1-29) amide infusion study showing sustained GH release during infusion.
2. Testing with growth hormone-releasing factor (GRF(1-29)NH2) and somatomedin C measurements for the evaluation of growth hormone deficiency
   human_physiology / pubmed_grf129_ghd_testing_1986
   GRF(1-29)NH2 GH-stimulation testing in young adult volunteers and children/adolescents.
3. Human growth hormone-releasing factor 1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats
   preclinical / pubmed_cjc1295_albumin_bioconjugate_2005
   Preclinical medicinal-biology source identifying CJC-1295 as a long-lasting GHRH analog; route and human benefit cannot be inferred from this alone.